Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes.

导出 LinkOut

翻译打印收藏纠错

作者： Dina,Abushanab ^[1] ; Salma,Chbib ^[1] ; Rasha,Kaddoura ^[1] ; Moza,Al Hail ^[1] ; Palli Valappila,Abdul Rouf ^[1] ; Wessam,El Kassem ^[1] ; Jassim,Shah ^[2] ; Ramesh Kumar,Ravindran Nair ^[2] ; Daoud,Al-Badriyeh ^[3]

作者单位： Department of Pharmacy, Hamad Medical Corporation, Doha, Qatar. ^[1] Department of Cardiology, Hamad Medical Corporation, Doha, Qatar. ^[2] College of Pharmacy, QU Health, Qatar University, Doha, Qatar. ^[3]

关键词 A A1 A19 B B1 B19 Dapagliflozin cost saving cost-effectiveness heart failure non-diabetes

主题词人类(Humans);心力衰竭(Heart Failure);糖尿病, 2型(Diabetes Mellitus, Type 2);费用效益分析(Cost-Benefit Analysis);每搏输出量(Stroke Volume);二苯甲基化合物(Benzhydryl Compounds);质量校正寿命(Quality-Adjusted Life Years);葡糖苷类(Glucosides)

DOI 10.1080/13696998.2024.2322258

PMID 38390641

发布时间 2024-03-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Journal of medical economics

404-417页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes.

Journal of medical economics

相似文献

Journal of medical economics

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes.

Journal of medical economics

相似文献

Journal of medical economics

相关期刊

检索历史清除